<DOC>
	<DOCNO>NCT01159561</DOCNO>
	<brief_summary>This study design determine safety immunogenicity WEE Vaccine Lot number 3-1-92 .</brief_summary>
	<brief_title>Western Equine Encephalitis Vaccine</brief_title>
	<detailed_description>Study Objectives : Primary : To assess safety Western Equine Encephalitis ( WEE ) Vaccine , Inactivated , TSI-GSD 210 , lot 3-1-92 . Secondary : To evaluate immunogenicity Western Equine Encephalitis ( WEE ) Vaccine , Inactivated , TSI-GSD 210 , lot 3-1-92 .</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalomyelitis , Equine</mesh_term>
	<mesh_term>Encephalomyelitis , Western Equine</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1855 year age In good health determine pertinent medical history , brief physical exam , vital sign , clinical safety laboratory evaluation Female : negative urine pregnancy test willing use reliable form contraception study duration Negative HIV antibody screen , seronegative HBsAg Hepatitis C antibody WEE , EEE , VEE , CHIK PRNT80 &lt; 1:10 Ability comprehend abnd willingness sign inform consent , include HIPAA separate HIV consent form Be willing comply followup visit , test , AE report Participant USAMRIID SIP Receipt vaccine investigational ; drug within 30 day prior study entry Anticipates receipt vaccine duration study ( influenza vaccination permit within 28 day WEE vaccination Acute chronic medical condition , medication , dietary supplement , PI 's opinion , would impair subject 's ability respond vaccination Hypersensitivity vaccine Allergic vaccine component : Human serum albumin , Neomycin Receipt anticipate receipt blood product study Female : Pregnant breastfeed Clinically significant abnormal laboratory test ( generally great equl 2 time upper limit normal determined PI )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>